Washington, DC, August 6, 2002 – Creation of the Plasma Proteome
Institute (PPI) was announced today in Washington, DC by Dr. Leigh Anderson, its
founder and CEO. The non-profit
Institute aims to enable major advances in disease diagnosis using results from
the expanding field of proteomics combined with new technologies for the
analysis of proteins in blood.
“New technologies exist for discovering and measuring
hundreds of disease-related proteins in standard doctor’s-office blood samples,
yet the translation of these possibilities into new life-saving diagnostic
tests remains painfully slow”, noted Dr. Anderson. “The early and correct diagnosis of disease is a critically
important component of medicine, one that helps patients receive the right
treatment and helps the pharmaceutical industry develop the best drugs. Through PPI we hope to bring together
the knowledge, technologies and people to produce a needed revolution in
disease diagnosis”.
Initial goals of PPI are to:
Dr. Leigh Anderson is joined in the founding of PPI by Dr.
Norman G. Anderson, who will serve as a Senior Scientific Advisor to the
Institute. The Andersons together
undertook the first systematic “proteomics” investigations of human plasma by
2-D electrophoresis in 1977. Prior
to founding PPI, the Andersons held senior management positions at Large Scale
Biology Corporation (Nasdaq: LSBC), whose proteomics division they founded in
1985. At LSBC, they developed the
first large-scale automated 2-D electrophoresis technology platform for
proteomics research, and pioneered a range of proteomics applications in drug
discovery, toxicology and plasma protein surrogate markers.
The Plasma Proteome Institute (PPI) is a private
non-profit institution located in Washington DC. PPI is working to promote the exploration and
diagnostic use of the plasma proteome as a means to better detect, understand
and treat disease. PPI cooperates
with researchers, institutions and companies interested in pursuit of plasma proteome
science.